al. showed that rGel/BLyS bound to BR3+/CD19+ cells from B-CLL patients and induced annexin V binding [29], suggesting the drug induces apoptosis of primary B-CLL cells. The gene discussed is ANXA5; the disease is B-cell chronic lymphocytic leukemia.